All Stories

  1. Role of Neuroglia in the Habenular Connection Hub of the Dorsal Diencephalic Conduction System
  2. Polymorphisms in the adrenergic neurotransmission pathway impact antidepressant response in depressed patients
  3. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity
  4. The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
  5. Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
  6. Circuits regulating pleasure and happiness – focus on potential biomarkers for circuitry including the habenuloid complex
  7. Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
  8. Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples
  9. A New Paradigm to Indicate Antidepressant Treatments
  10. Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression
  11. Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment‐free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design
  12. Association of PIP4K2A Polymorphisms with Alcohol Use Disorder
  13. W86. FTO GENE POLYMORPHISMS AND BODY MASS INDEX IN SCHIZOPHRENIA PATIENTS WITH METABOLIC SYNDROME
  14. Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
  15. Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
  16. Clinical Evaluation of Different Treatment Strategies for Motor Recovery in Poststroke Rehabilitation during the First 90 Days
  17. Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
  18. Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
  19. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
  20. Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
  21. Putative role of vitamin D in the mechanism of alcoholism and other addictions – a hypothesis
  22. P.541 Inflammation in schizophrenia with metabolic syndrome: features of the cytokine spectrum
  23. P.143 Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples
  24. P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients
  25. Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
  26. Genetic polymorphisms of PIP5K2A and course of schizophrenia
  27. Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
  28. Neurobiological mechanisms associated with antipsychotic drug-induced dystonia
  29. Serum BDNF’s Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke
  30. COMT gene polymorphism and antipsychotic- induced hyperprolactinemia in schizophrenia patients
  31. Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
  32. 5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
  33. Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression
  34. Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
  35. Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
  36. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
  37. Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
  38. Abstracts of the 86th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) With contribution of the Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V. (AGAH)
  39. Diagnose, indicate, and treat severe mental illness (DITSMI) as appropriate care: A three-year follow-up study in long-term residential psychiatric patients on the effects of re-diagnosis on medication prescription, patient functioning, and hospital be...
  40. Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
  41. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients
  42. P.374 Cortisol and DHEAS related to metabolic side effects in patients with schizophrenia
  43. P.390 Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome
  44. P.505 The potential role of BDNF and prolactin genotypes on antidepressant response in depressive patients
  45. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
  46. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia
  47. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
  48. A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
  49. Consider Role of Glutamatergic Habenula-projecting Globus Pallidus in OCD
  50. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors
  51. No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia
  52. Apolipoprotein serum levels related to metabolic side effects in patients with schizophrenia
  53. Genes of neurotrophic factors and responsiveness to antidepressive psychopharmacotherapy in patients with depressive disorders
  54. Tardive dyskinesia in schizophrenia: Gene polymorphisms of muscarinic and adrenergic receptors
  55. The risk prediction of development of neuroleptic hyperprolactinemia based on genetic markers
  56. The study of dopamine receptor genes in patients with schizophrenia
  57. The evolutionary old forebrain as site of action to develop new psychotropic drugs
  58. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia
  59. Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning
  60. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
  61. Terug naar de basis: een andere focus bij neuro-psycho-biologisch onderzoek
  62. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine
  63. Commentary on “A non-reward attractor theory of depression”: A proposal to include the habenula connection
  64. How brain mechanism of feeling pleasure and happiness evolved during the last 560 million years.
  65. Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia
  66. Dopamine receptors genes polymorphisms in Parkinson patients with levodopa-induced dyskinesia
  67. Potential biomarkers of tardive dyskinesia: a multiplex analysis of blood serum
  68. Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson’s disease
  69. The role of the habenula in the transition from reward to misery in substance use and mood disorders
  70. Circuits regulating pleasure and happiness: evolution and role in mental disorders
  71. Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics
  72. Association Between Prolactin Gene Polymorphism (–1149 G/T) and Hyperprolactinemia in Anti-psychotic Treated Patients with Schizophrenia
  73. Biomarkers of depressive disorders: A multiplex analysis of blood serum
  74. Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders
  75. Circuits Regulating Pleasure and Happiness in Bipolar Disorder
  76. Association of СОМТ gene polymorphisms with Parkinson’s disease
  77. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: The Dutch GHB monitor project
  78. Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions
  79. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
  80. Circuits Regulating Pleasure and Happiness: The Evolution of the Amygdalar-Hippocampal-Habenular Connectivity in Vertebrates
  81. Circuits Regulating Pleasure and Happiness—Mechanisms of Depression
  82. Gene polymorphism of neurotransmitter transporters in schizophrenic patients with drug-induced hyperprolactinemia
  83. Gene polymorphism of serotonin receptors and drug-induced hyperprolactinemia in schizophrenic patients
  84. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia
  85. Comments on Lucire and Crotty, 2011
  86. The Effect of Co-occurring Substance Use on Gamma-hydroxybutyric Acid Withdrawal Syndrome
  87. Circuits regulating pleasure and happiness in major depression
  88. The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review
  89. Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding
  90. Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates
  91. P.5.d.005 Polymorphisms of DRD2, DRD3, DRD4 and HTR2C genes in levodopa-induced dyskinesias in Parkinson's disease
  92. Baclofen as Relapse Prevention in the Treatment of Gamma-Hydroxybutyrate Dependence
  93. New Studies On Clozapine Treatment in Psychosis
  94. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility
  95. Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
  96. Practical recommendations for improvement of the physical health care of patients with severe mental illness
  97. Evaluation of health promotion programmes in severe mental illness: theory and practice
  98. Poster #S267 IMPROVING SOMATIC HEALTH OF OUTPATIENTS WITH SEVERE MENTAL ILLNESS
  99. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia
  100. EPA-0301 – Improving somatic health of outpatients with severe mental illness
  101. No news without new scientific ideas
  102. Reply
  103. Improvement of care for the physical health of patients with severe mental illness: a qualitative study assessing the view of patients and families
  104. Is Somatic Health Screening in Patients With Severe Mental Illness of Added Value?
  105. Evaluating interventions to improve somatic health in severe mental illness: a systematic review
  106. New insights into the mechanism of drug-induced dyskinesia
  107. Are immediate‐ and extended‐release drugs interchangeable?
  108. Influencing CYP Enzymes to Boost Psychiatric Treatment: A Review on Clinical Evidence
  109. Little hope for further innovations in psychopharmacology?
  110. Gaps in health care for the somatic health of outpatients with severe mental illness
  111. Abstracts from the 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Sweden, 3–7 June 2012
  112. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia
  113. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia
  114. Behandeling met medicatie
  115. Substantial skin disorders in psychiatric illness coincide with diabetes and addiction
  116. Reply
  117. The Mechanism of Drug-induced Akathisia
  118. Risk Factors for Overweight and Diabetes mellitus in Residential Psychiatric Patients
  119. Treatment adherence therapy in people with psychotic disorders: randomised controlled trial
  120. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders
  121. Skin disorders in chronic psychiatric illness
  122. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia
  123. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia
  124. Evidence That Patients With Single Versus Recurrent Depressive Episodes Are Differentially Sensitive to Treatment Discontinuation
  125. Visualizing Pharmacological Activities of Antidepressants: A Novel Approach
  126. A cross-sectional study of prescribing patterns in chronic psychiatric patients living in sheltered housing facilities
  127. Measuring Movement Disorders in Antipsychotic Drug Trials
  128. Adding and Switching Antipsychotics
  129. P.2.g.006 Effectiveness of a combination of Hypericum and Passiflora for the treatment of depression with concomitant anxiety
  130. P.2.b.001 Treatment with electroconvulsive therapy is associated with an increase of nitric oxide synthesis
  131. Letter
  132. Hypothermia following antipsychotic drug use
  133. Treatment with ect is associated with an increase of nitric oxide
  134. Understanding and Improving Treatment Adherence in Patients with Psychotic Disorders: A Review and a Proposed Intervention
  135. Aripiprazole in chronic schizophrenia: experiences in daily practice
  136. Neurobiologie van cognitieve en emotionele motivatie
  137. 3 Biologische therapievormen
  138. Bipolar mania and plasma amino acids: Increased levels of glycine
  139. Nitric Oxide and Neopterin in Bipolar Affective Disorder
  140. Seksuele motivatie: meer dan dopaminerge stimulatie van het ventrale striatum
  141. Dyspepsia in Chronic Psychiatric Patients
  142. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study
  143. Indeling en bijwerkingen van psychofarmaca
  144. Cardiovascular Risk Factors in Outpatients with Bipolar Disorder
  145. Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage
  146. Retrospective evaluation of the effect of omeprazole on clozapine metabolism
  147. Responsivity to Stress in Chronic Posttraumatic Stress Disorder Due to Childhood Sexual Abuse
  148. P.2.035 Risperidone versus zuclopentixol in acute psychosis in emergency psychiatry: A prospective naturalistic study
  149. P.2.083 Pilot study of the effects of rivastigmine in schizophrenia
  150. The influence of zinc on the uptake of vitamin B12 by the cerebrospinal fluid
  151. Outcomes and costs of treatment with risperidone in adult and elderly patients: the Delta patient using risperidone study
  152. Dyspepsia in chronic psychiatric patients
  153. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): inter-rater reliability and construct validity
  154. Side effects of psychiatric-medication in a large population of chronically admitted psychiatric patients
  155. Concurrent validity and sensitivity to change of the SADIMoD
  156. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test–retest reliability and concurrent validity
  157. Comparison of indications and treatment outcomes of risperidone in elderly and younger patients
  158. Test-retest reliability and concurrent validity of the SADIMoD
  159. Cardiovascular risk factors and lithium in bipolar disorder
  160. Interrater reliability and construct validity of the SADIMoD
  161. Neuroendocrinological, biochemical and psychophysiological characteristics of chronic posttraumatic stress disorder
  162. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study
  163. Concomitant use of mirtazapine and risperidone: A pilot study
  164. Effect of blood collection tubes on tricyclic antidepressant blood levels
  165. Figure copying in patients with schizophrenia: Relationship between negative symptoms and the complexity of figures
  166. P.2.034 Tremor in schizophrenic patients treated with antipsychotics
  167. Psychomotor slowing in depression and schizophrenia
  168. Influence of Heparin on the Assay of Amitriptyline, Clomipramine, and Their Metabolites
  169. Dealing with sadness, madness and hostility
  170. A Comparison of Carbamazepine Divitabs and a Normal Carbamazepine Preparation in Psychiatric and Oligophrenic Patients
  171. Is Diltiazem Effective in Treating the Symptems of (Tardive) Dyskinesia in Chronic Psychiatric Inpatients? A Negative, Double-Blind, Placebo-Controlled Trial
  172. Is Diltiazem Effective in Treating the Symptoms of (Tardive) Dyskinesia in Chronic Psychiatric Inpatients? A Negative, Double-Blind, Placebo-Controlled Trial
  173. Continuation and maintenance therapy with antidepressive agents
  174. Continuation and maintenance therapy with antidepressive agents
  175. A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients
  176. Halopemide, a new psychotropic agent
  177. Receptorinteracties in vivo en in vitro
  178. Effects of halopemide on GABA receptor binding, uptake and release
  179. Ceratoniapitten bij uremie
  180. Chenodesoxycholzuur, een tumor-promotor?
  181. Boekbesprekingen
  182. Boekbesprekingen
  183. Referaten
  184. The regional localization of R28935 in the cat brain as dependent on the route of administration
  185. Regional distribution of halopemide, a new psychotropic agent, in the rat brain at different time intervals and after chronic administration
  186. Regional localization of halopemide, a new psychotropic agent, in the rat brain
  187. The regional localisation of a new potent centrally acting antihypertensive agent R 28935 and its less active threo-isomer R 29814 in the cat brain